Valuation : Regeneron Pharmaceuticals, Inc.

Market Cap 78.04B 400B 67.3B 63.68B 57.73B 108B 7,456B 109B 756B 291B 3,789B 293B 287B 11,983B P/E 2026 *
18.1x
P/E 2027 * 15.5x
Enterprise Value 70.86B 363B 61.11B 57.83B 52.42B 98.28B 6,770B 98.86B 686B 264B 3,441B 266B 260B 10,881B EV / Sales 2026 *
4.19x
EV / Sales 2027 * 3.68x
Free-Float
71.06%
Yield 2026 *
0.5%
Yield 2027 * 0.56%
1 day-1.76%
1 week-5.94%
Current month-2.35%
1 month-3.85%
3 months+27.79%
6 months-0.66%
Current year-6.22%
1 week 66.5
Extreme 66.5
70.6
1 month 64.6
Extreme 64.6
72.93
Current year 50
Extreme 50
73.16
1 year 49.24
Extreme 49.24
73.33
3 years 44.82
Extreme 44.82
111.72
5 years 44.82
Extreme 44.82
111.72
10 years 18.16
Extreme 18.160832
111.72
Manager TitleAgeSince
President 66 2000-12-31
Chief Executive Officer 73 1988-01-07
Director of Finance/CFO 55 2024-02-04
Director TitleAgeSince
Chairman 73 2023-06-08
Director/Board Member 85 1991-05-31
Director/Board Member 85 1991-05-31
Change 5-day change 1-year change 3-year change Capi.($)
-1.76%-5.94% - - 78.02B
-1.48%-5.59%+37.54%-6.24% 78.02B
-1.42%-4.24%-18.81%-37.78% 57.4B
+5.38%-1.09%+467.03%+36.08% 57.48B
-0.56%-2.21%-11.17%+25.38% 48.81B
+1.93%-2.37%-2.00%+149.45% 45.5B
+0.80%-1.67%+45.89%-16.13% 32.08B
-1.47%-4.17%+40.97%+88.59% 24.62B
-0.85%-8.64%-3.66%+144.26% 20.77B
-0.09%-3.61%+63.58%+97.66% 15.75B
Average +0.05%-3.87%+68.82%+53.47% 42.27B
Weighted average by Cap. +0.01%-3.71%+82.71%+35.89%

Financials

2026 *2027 *
Net sales 16.93B 86.77B 14.6B 13.81B 12.52B 23.48B 1,617B 23.61B 164B 63.02B 822B 63.57B 62.16B 2,599B 18.48B 94.75B 15.94B 15.08B 13.67B 25.63B 1,766B 25.79B 179B 68.82B 897B 69.42B 67.88B 2,838B
Net income 4.77B 24.47B 4.12B 3.9B 3.53B 6.62B 456B 6.66B 46.23B 17.77B 232B 17.93B 17.53B 733B 5.45B 27.91B 4.7B 4.44B 4.03B 7.55B 520B 7.6B 52.74B 20.28B 264B 20.45B 20B 836B
Net Debt -7.17B -36.76B -6.18B -5.85B -5.31B -9.95B -685B -10.01B -69.46B -26.7B -348B -26.93B -26.34B -1,101B -10.05B -51.54B -8.67B -8.21B -7.44B -13.95B -961B -14.03B -97.38B -37.44B -488B -37.76B -36.93B -1,544B
Logo Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from collaboration agreements (51.1%): collaboration with Sanofi (80.3% of revenues), Bayer (19.4%) and other (0.3%); - revenues from product sales (30%); - revenues from sales of technology licenses and subcontracted research services (4.9%). At the end of 2025, the group had a portfolio of approximately 45 products in clinical development.
Employees
15,410
Date Price Change Volume
26-09-11 R$66.50 -1.76% 8
26-09-10 R$67.69 -1.17% 506
26-09-09 R$68.49 -2.73% 131
26-09-08 R$70.41 -0.41% 27
26-09-04 R$70.70 -1.19% 1,136
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
781.49USD
Average target price
849.32USD
Spread / Average Target
+8.68%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!